Flow cytometrical DNA- and clinical parameters in the prediction of prognosis in stage I-II endometrial carcinoma.
In almost all studies regarding flow cytometry and endometrial carcinoma, the DNA factors used are stronger prognostic parameters than the clinical factors previously used. Number of sub-populations and/or percentage of cells in S-phase are mostly used to select those tumors with the worst prognosis. In this study, reporting the 2 year follow-up of 245 patients (222 followed for more than 2 years), we claim that the DNA-index is a stronger prognostic tool than other DNA parameters, but also that the range of myometrial invasion is a stronger predictor than all other parameters including the DNA. Range of myometrial invasion and DNA index are used to form one high-risk group, consisting of 22% of the patients with a relapse rate of 38%, and one low-risk group, consisting of 47% of the patients with a relapse rate of 4%.
Lindahl
B
B
Department of Obstetrics and Gynecology, Lund University, Sweden.
Gullberg
B
B
D004273:DNA, Neoplasm / Q000032:analysis*; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D009215:Myometrium / Q000473:pathology; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011003:Ploidies; D011379:Prognosis; D016196:S Phase; D014594:Uterine Neoplasms / Q000473:pathology*
D004273:DNA, Neoplasm